MedTrace Logo

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

NCT07167511 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1730

Last updated 2025-09-11

No results posted yet for this study

Summary

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify factors influencing treatment failure. A multicenter retrospective analysis was conducted and study outcomes included eradication rates and incidence of adverse events.

Conditions

  • Helicobacter Pylori Infection

Interventions

OTHER

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Zaozhuang Municipal Hospital

    collaborator OTHER

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • Qihe County People's Hospital

    collaborator UNKNOWN

  • Taierzhuang District People's Hospital

    collaborator OTHER

  • University Town Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Dezhou Hospital Qilu Hospital of Shandong University

    collaborator OTHER

  • Yueyue Li

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-31
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07167511 on ClinicalTrials.gov